.. den Tesetaxel Studien in Japan. Denn in Japan, ist der Einsatz als Anti-Krebsmittel gegen Magenkrebs bedeutend, weil dort die Magenkrebsrate hoch ist und man dort wohl auch genügend Teilnehmer für die Studien findet.
"About the New Trial. Genta has made it clear that gastric cancer is the primary indication for tesetaxel’s registration studies, so conducting a study in East Asia is part of the natural evolution of the program. Gastric cancer is the fourth most common cancer worldwide, however its incidence ranks first or second in most East Asian countries, including Japan, Korea, Taiwan, and China. In this study, oral tesetaxel will be evaluated over a limited dosing-range as a single agent in patients with advanced gastric cancer. This trial will be conducted at Kinki University in Osaka and will serve as starting point for Genta’s new initiative to explore tesetaxel’s ability to treat patients with cancer on a global basis. We look forward to hearing more about this study from the Company." |
Thread abonnieren
